(lp0
S"Why ImmunoGen, Inc. Skyrocketed Higher Today Motley Fool - Feb 27, 2017 It's also possible investors are buying ahead of the Society of Gynecologic Oncology's Annual Meeting of Women's Cancer next month where ImmunoGen is scheduled to present additional phase 1 data from a subset of patients getting its cancer medication&nbsp;...ImmunoGen Inc  Has A Wave Of Catalysts About To Hit Press - Insider FinancialImmunoGen, Inc.  Update On Trial of Mirvetuximab Soravtansine - Journal Transcript"
p1
aS"Here's Why ImmunoGen, Inc. Skyrocketed 45% in February Motley Fool - Mar 9, 2017 Shares of ImmunoGen , a small-cap biopharmaceutical company that utilizes its proprietary antibody-drug conjugate  technology to fight various forms of cancer, skyrocketed 45% during February, according to data from S&amp;P Global&nbsp;...The 4.5% Stake of ImmunoGen, Inc.  Owned by Primecap Management Company - DailyQuintImmunoGen, Inc.  Cut to Hold at Zacks Investment Research - BBNS"
p2
aS'Revenue Approximations Analysis: Keryx Biopharmaceuticals, Inc. (KERX ... StockNewsJournal - 16 hours ago ImmunoGen, Inc. , at its latest closing price of $3.72, it has a price-to-book ratio of 0.00, compared to an industry average at 9.86.'
p3
aS'ImmunoGen, Inc.  Downgraded to Hold at Zacks Investment Research Chaffey Breeze - 4 hours ago ImmunoGen, Inc. logo Zacks Investment Research downgraded shares of ImmunoGen, Inc.  from a buy rating to a hold rating in a report released on Monday.ImmunoGen, Inc.  Insider Ownership stands at 2 - The Newburgh PressAnalytical Guide for ImmunoGen, Inc. , Immune Pharmaceuticals, Inc ... - The USA Commerce'
p4
aS"3 Charts That Show the Potential Risks and Rewards for Immunogen, Inc. Stock Motley Fool - Mar 4, 2017 After 36 years of being in business, Immunogen  has yet to make a profit. Unfortunately, the biotech still isn't close to reaching break-even status."
p5
aS'Are ImmunoGen, Inc.  Stock Technicals Favorable? USA Commerce Daily - 15 hours ago With all other things going on, ImmunoGen, Inc.  has been on a run - rising 138.46 percent in just three months.'
p6
aS"Taking a Fresh Look at ImmunoGen, Inc.  StockNewsJournal - Mar 23, 2017 ImmunoGen, Inc.  is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $3.60, down from yesterday's close by -0.28%."
p7
aS'ImmunoGen, Inc.  Brokerage Firm Stock Target Update Aiken Advocate - 10 hours ago Equity analysts have a short-term target price of $4.26 on shares of ImmunoGen, Inc. . This consensus data is compiled by Zacks Research.'
p8
aS'What Are Analysts Suggestions On ImmunoGen, Inc.  News Oracle - 18 hours ago ImmunoGen, Inc.  will report its next earnings on Apr 27 - May 1 . The company reported the earnings of $-0.39/Share in the last quarter where the estimated EPS by analysts was $-0.38/share.'
p9
aS"ImmunoGen's Mirva May Have Activity In FR High Ovarian Cancer Seeking Alpha - Mar 20, 2017 Immunogen  is a nanocap clinical stage biopharma developing Mirventuximab soravtansine, an antibody-drug conjugate  with a monoclonal antibody  that binds to FRalpha-positive tumor cells thereby delivering&nbsp;..."
p10
a.